Clinical trial
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
NCT00319852 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00319852 |
|---|---|
| Title | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pertussis, Diphtheria, Poliomyelitis, Tetanus |
| Intervention type | Biological |
| Interventions | DTaP-IPV combined vaccine, DTaP vaccine |
| Enrollment | 442 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 16, 2012 |
| Countries | South Korea |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: